Major histocompatibility complex class I presentation of exogenously acquired minor alloantigens initiates skin allograft rejection

Major histocompatibility complex (MHC) class I molecules present peptides from endogenous proteins. However, in some cases class I-restricted peptides can also derive from exogenous antigens. This MHC class I exogenous presentation could be involved in minor histocompatibility antigen (mHAg)-disparate allograft rejection when donor alloantigens are not expressed in graft antigen-presenting cells (APC) that initiate the rejection mechanism. Here we addressed this question by using a skin graft experimental model where donors (H-2(b) Or H-2(d) Tg beta-gal mice) expressed the mHAg like beta-galactosidase (beta-gal) in keratinocytes but not in Langerhans' cells (LC) which have an APC function. Rejection of Tg beta-gal skin by a beta-gal-specific CD8 cytotoxic T lymphocyte (CTL) effector mechanism should require presentation by donor and/or recipient LC of MHC class I-restricted peptides of exogenous beta-gal shed by keratinocytes. Indeed, our results showed that 1) H-2(b) Tg beta-gal skin was rejected by H-2(bxs) and H-2(bxd) recipients; 2) rejection was mediated by beta-gal-specific CD8(+) CTL effectors; and 3) H-2(bxd) mice having rejected H-2(b) Tg beta-gal skin generated beta-gal-specific CTL restricted by H-2(b) and H-2(d) class I molecules and rejected subsequently grafted H-2(d) Tg beta-gal skin in an accelerated fashion, demonstrating that recipient LC have presented exogenous (beta-gal-derived MHC class I epitopes. These results lead to the conclusion that MHC class I exogenous presentation of donor mHAg can initiate allograft rejection.